Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6088925 | 0.90 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDMAPTSMN1; SMN2 | |
| SCHEMBL6091130 | 0.88 | KDM4E (0.39) | ALDH1A1KDM4EHPGDMAPTSMN1; SMN2 | |
| SCHEMBL6090310 | 0.88 | MAPT (0.43) | ALDH1A1KDM4EHPGDMAPTSMN1; SMN2 | |
| SCHEMBL6091358 | 0.88 | KDM4E (0.39) | ALDH1A1KDM4EHPGDMAPTSMN1; SMN2 | |
| SCHEMBL6092154 | 0.88 | GAA (0.40) | ALDH1A1KDM4EHPGDMAPTSMN1; SMN2 | |
| SCHEMBL6092303 | 0.85 | KDM4E (0.39) | ALDH1A1KDM4EHPGDMAPTSMN1; SMN2 | |
| SCHEMBL6091282 | 0.85 | KDM4E (0.48) | ALDH1A1KDM4EHPGDMAPTGAA | |
| SCHEMBL6089743 | 0.84 | LMNA (0.44) | ALDH1A1KDM4EHPGDMAPTSMN1; SMN2 | |
| SCHEMBL6089858 | 0.83 | LMNA (0.42) | MEN1KMT2A | |
| SCHEMBL6092226 | 0.82 | TNKS2 (0.45) | ALDH1A1KDM4EHPGDMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1582520-A1 | NOVEL PARP INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | PARP1, PARP2, PARP11 | ALDH1A1 1890/4885KDM4E 812/4885HPGD 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.